Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2025-12-25 @ 12:14 AM
NCT ID:
NCT04939558
Eligibility Criteria:
Inclusion Criteria:
* Age \> 18 years
* Healthy volunteer (with no previous or current chronic cardiorespiratory diagnoses)
One of the following cardiorespiratory diagnoses:
* COPD (GOLD 1, 2, 3 / A, B, C)\*
* Asthma (mild to moderate, not labelled as severe)\*
* Congestive cardiac failure\*
* Anaemia (with at least 50% of participants recruited having no history of chronic cardiorespiratory conditions)\*
* Bronchiectasis (acquired or genetic, e.g. cystic fibrosis or other primary ciliary dyskinesias)\*
* Lung cancer (including rare types e.g. mesothelioma)\*
* Interstitial Lung Disease (including pulmonary fibrosis pneumoconiosis, asbestosis, sarcoidosis, amyloidosis)\*
* Long COVID\*
* Upper airway obstruction disorder\*
* \[Active pulmonary hypertension\]
* \[Extrinsic Allergic Alveolitis\]
* \[Active pulmonary embolism\]
Exclusion Criteria:
* Participants who, in the opinion of the chief investigator, or their delegate, are unlikely to comply with the requirements of the study;
* Diagnosis of neuromuscular disorders;
* Concurrent diagnosis of cardiorespiratory conditions (other than those listed in the inclusion criteria above) that, in the opinion of the chief investigator, would impact the conduct of the study
* Participants who are acutely unwell, e.g. active exacerbation, very short of breath e.g. severe COPD (GOLD 4 / D) or end-stage IPF.
* Inability to give written informed consent
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04939558
Study Brief:
Protocol Section:
NCT04939558